Hims & Hers Faces 2026 Growth Challenge as Wegovy Subscriber Churn Risks Rise
Hims & Hers Faces 2026 Growth Challenge as Wegovy Subscriber Churn Risks Rise
Hims & Hers Health may face a difficult path to meeting its 2026 revenue targets as analysts warn that customer churn linked to its oral Wegovy subscription model could pressure future sales growth.
According to Bank of America analysts cited by Proactive, Hims & Hers would need to add about 225,000 new oral Wegovy subscribers per quarter from the second through fourth quarters of 2026 to reach the midpoint of its full-year sales guidance. That would represent around 45% of all projected new U.S. cash-pay oral Wegovy patients, a level analysts described as a challenging target.
Subscription Price Increase Could Raise Churn Risk
A major concern is the company’s pricing structure. The oral Wegovy subscription reportedly starts at $39 for the first month before rising to $149 in later months. Bank of America believes this price jump may lead some customers to cancel or leave the platform, creating a possible revenue drag.
The analysts estimated that higher churn could create an $85 million compounding revenue headwind by the fourth quarter of 2026 if grandfathered patients exit the service. Under a more favorable churn scenario, the revenue impact could be closer to $25 million, making the company’s guidance easier to reach.
Large Market Opportunity, But Tough Competition
The overall market opportunity remains significant. BofA projects that the U.S. cash-pay oral Wegovy patient pool could grow by about 1.5 million incremental patients from the second through fourth quarters of 2026. This equals roughly 170,000 new cash-pay patients per month.
However, capturing enough of that market may not be easy. Hims & Hers has previously held a strong share of new telehealth customers in this category, but maintaining that level could become harder as more patients compare prices, treatment options, insurance coverage, and competing telehealth providers.
April Data Shows Some Positive Momentum
There was one encouraging sign in the latest data. BSM data cited by Bank of America showed that Hims & Hers’ share of new observed telehealth customers improved to about 46% in April. This marked a rebound from the 29% to 34% range seen between January and March.
Bank of America noted that Hims & Hers has historically captured about 40% to 50% of new customers in the segment. Even so, analysts warned that keeping this pace through the second half of 2026 could be difficult because customer retention remains uncertain.
Retention Is the Key Issue for GLP-1 Growth
Retention is becoming one of the most important factors for companies selling GLP-1 weight-loss treatments. IQVIA data cited in the report showed that branded Wegovy persistence is relatively low, with retention around 42% by month six.
Bank of America’s model assumes Hims & Hers may see about 53% retention by month three and only 22% retention by month six. This means the company may need a steady flow of new customers just to offset cancellations and keep revenue moving higher.
Competitor Ro Shows Mixed Read-Through
Analysts also pointed to early cohort data from competitor Ro, where returning customers increased after the oral Wegovy launch. This was viewed as a positive sign for demand in the broader market.
Still, Bank of America cautioned that Ro’s data may not fully apply to Hims & Hers. Ro accepts insurance and may use stricter patient screening, while Hims & Hers’ model is more focused on cash-pay customers. These differences could affect customer behavior and long-term retention.
Bank of America Cuts Price Target
Following its updated analysis, Bank of America kept a Neutral rating on Hims & Hers and lowered its price objective to $25 from $28. The reduced target reflects concerns that the company’s 2026 guidance may be harder to achieve if churn rises and subscriber growth falls short.
What This Means for Investors
For investors, the main question is whether Hims & Hers can keep attracting enough new oral Wegovy customers while also improving retention. The company operates in a fast-growing weight-loss treatment market, but growth alone may not be enough if customers leave after only a few months.
If Hims & Hers can sustain strong market share and reduce churn, its 2026 outlook could remain within reach. However, if the price increase causes more cancellations than expected, the company may face pressure on revenue, margins, and investor confidence.
Conclusion
Hims & Hers remains a notable player in the digital health and weight-loss treatment space, but Bank of America’s latest analysis highlights a clear challenge. The company must balance aggressive subscriber growth with stronger customer retention to meet its 2026 goals.
With oral Wegovy demand expected to grow, the opportunity is real. Yet the road ahead may be steep, especially if churn increases after the first-month promotional price ends. Investors will likely watch upcoming subscriber trends, retention data, and pricing performance closely.
#HimsAndHers #Wegovy #GLP1 #DigitalHealth #SlimScan #GrowthStocks #CANSLIM